newscontact us

Cesca Therapeutics Submits pre-IDE Information Package to FDA for Surgwerks(TM) CLI therapy System

Company to Meet FDA and Receive Feedback During Summer 2014

RANCHO CORDOVA, Calif., March 26, 2014 (GLOBE NEWSWIRE) — Cesca Therapeutics, Inc. (Nasdaq:KOOL), an autologous cell based regenerative medicine company, announced it has submitted a pre-IDE (Investigational Device Exemption) information package to the U. S. Food and Drug Administration (FDA) for the use of the SurgWerks™ CLI Therapy designed to treat no option patients with late stage critical limb ischemia (CLI).

032614 CLI Pre-IDE PR Final